Columns & Departments
Drug & Device News
In-depth discussion of a recent case involving pelvic mesh.
Why Is It So Hard to Find Quality Medical Malpractice Verdict Data?
In an era of incredible "big data," the medical malpractice practitioner should ask, "Why are there no accurate, reliable, and statistically valid measurements of malpractice verdicts by subject and jurisdiction?"
Columns & Departments
Verdicts
In-depth discussion of two pivotal rulings.
Entitlement to a Credit for a Settlement Reached in Another Jurisdiction
This article addresses the dynamics of New Jersey's Collateral Source doctrine and defendant physician's entitlement to a credit for a settlement that a plaintiff reached in another jurisdiction.
Columns & Departments
Med Mal News
Discussion of two major cases.
Features
Surviving the Medical Malpractice Claim
When a doctor or other health care provider learns that he or she is the subject of a medical malpractice suit, one of the first things the defendant will want to do is find the most top-flight legal representation possible. But how can the physician know which defense attorney is the right one for the case?
Columns & Departments
Drug & Device News
Analysis of several major cases.
Features
Why Is It So Hard to Find Quality Medical Malpractice Verdict Data?
In an era of incredible "big data," the medical malpractice practitioner should ask, "Why are there no accurate, reliable, and statistically valid measurements of malpractice verdicts by subject and jurisdiction?"
Columns & Departments
Drug & Device News
Recent news of importance.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- Bankruptcy Sales: Finding a Diamond In the RoughThere is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- The DOJ's Latest Opioid Crime-Fighting Tool: The Civil False Claims Act<b><i>The U.S. Department of Justice Is Now Using The False Claims Act — Traditionally a Civil Enforcement Tool — to Combat the United States' Sweeping Opioid Epidemic</b></i><p>The use of the FCA is part of a larger DOJ strategy to develop multi-faceted solutions for this public health emergency.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
